TOPLINE:

When used as first-line therapy in patients with type 2 diabetes (T2D), GLP-1 receptor agonists (RAs) seemed to be more effective than metformin at reducing the risk for dementia, particularly Alzheimer’s disease and other nonvascular types, with this benefit being more pronounced in older adults and women.

METHODOLOGY:

Both GLP-1 RAs and metformin have shown potential neuroprotective effects in patients with T2D, but no direct comparisons have evaluated their relative efficacy in preventing dementia.

Researchers conducted a retrospective cohort study using data from a global health research network to compare the risk for dementia in patients with T2D who initiated either GLP-1 RAs or metformin as first-line monotherapy between 2004 and 2024.

They included 87,229 propensity

See Full Page